Findings

What do systematic reviews say?

4,811 questions · 70,850 findings · 5,139 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,174 · 21.4%GRADE not reported 6,479 · 9.1%Very low 17,330 · 24.5%Low 17,814 · 25.1%Moderate 11,056 · 15.6%High 2,997 · 4.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.56 [0.5, 0.63]
3 studies · 1564 participants
Moderate

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 486 participants
Low

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Chemotherapy with bevacizumab followed by bevacizumab maintenance leads to higher any adverse event (grade ≥3) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.11 [1.07, 1.16]
3 studies · 1538 participants
High

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Bowel fistula / perforation (grade ≥ 3) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Overall survival (OS) · platinum‐sensitive recurrent EOC

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.86 [0.67, 1.11]
1 study · 282 participants
Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

Chemotherapy with TKI followed by TKI maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.56 [0.44, 0.72]
1 study · 282 participants
Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 146 participants
Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

QoL · newly‐diagnosed EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 890 participants
High

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Bowel fistula / perforation (grade ≥ 3) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bevacizumab plus chemotherapy vs chemotherapy alone

Overall survival (OS) · recurrent platinum‐resistant EOC

Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.73 [0.61, 0.86]
5 studies · 778 participants
High

Bevacizumab plus chemotherapy vs chemotherapy alone

Progression‐free survival · recurrent platinum‐resistant EOC

Chemotherapy with bevacizumab probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.49 [0.42, 0.58]
5 studies · 778 participants
Moderate

Bevacizumab plus chemotherapy vs chemotherapy alone

Quality of life · recurrent platinum‐resistant EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bevacizumab plus chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC

Chemotherapy with bevacizumab showed no clear difference in any adverse event grade ≥ 3 compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.68 [0.76, 3.69]
1 study · 101 participants
Low

Bevacizumab plus chemotherapy vs chemotherapy alone

Hypertension (grade ≥ 2) · recurrent platinum‐resistant EOC

Chemotherapy with bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 3.11 [1.83, 5.27]
2 studies · 436 participants
Low

Bevacizumab plus chemotherapy vs chemotherapy alone

Bowel fistula / perforation (grade ≥ 2) · recurrent platinum‐resistant EOC

Chemotherapy with bevacizumab showed no clear difference in bowel fistula / perforation (grade ≥ 2) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 6.89 [0.86, 55.09]
2 studies · 436 participants
Low

Chemotherapy with TKI vs chemotherapy alone

Overall survival (OS) · recurrent platinum‐resistant EOC

Chemotherapy with TKI showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.85 [0.68, 1.08]
8 studies · 940 participants
Moderate

Chemotherapy with TKI vs chemotherapy alone

Progression‐free survival · recurrent platinum‐resistant EOC

Chemotherapy with TKI may leads to lower progression‐free survival (PFS) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.7 [0.55, 0.89]
8 studies · 940 participants
Low